The insulin resistance syndrome (IRS) is considered to be a new target of risk-reduction therapy. The IRS is a cluster of closely associated and interdependent abnormalities and clinical outcomes that occur more commonly in insulinresistant/hyperinsulinemic individuals. This syndrome predisposes individuals to type 2 diabetes, cardiovascular diseases, essential hypertension, certain forms of cancer, polycystic ovary syndrome, nonalcoholic fatty liver disease, and sleep apnea. In patients at high risk for cardiovascular diseases, endothelial dysfunction is observed in morphologically intact vessels even before the onset of clinically manifest vascular disease. Indeed, there are several lines of evidence that indicate that endothelial function is compromised in situations where there is reduced sensitivity to endogenous insulin. It is well established that a decreased bioavailability of nitric oxide (NO) contributes to endothelial dysfunction. Furthermore, NO may modulate insulin sensitivity. Activation of NO synthase (NOS) augments blood flow to insulinsensitive tissues (i.e. skeletal muscle, liver, adipose tissue), and its activity is impaired in insulin resistance. Inhibition of NOS reduces the microvascular delivery of nutrients and blunts insulin-stimulated glucose uptake in skeletal muscle. Furthermore, induction of hypertension by administration of the NOS inhibitor N G -monomethyl-L-arginine is also associated with insulin resistance in rats. Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial vasodilator dysfunction and increased risk of cardiovascular diseases. An intriguing relationship exists between insulin resistance and ADMA. Plasma levels of ADMA are positively correlated with insulin resistance in nondiabetic, normotensive people. New basic research insights that provide possible mechanisms underlying the development of insulin resistance in the setting of impaired NO bioavailability will be discussed.
Introduction
Sensitivity to insulin-mediated glucose disposal varies widely in the population. 1 When insulin-resistant individuals are not able to maintain the degree of hyperinsulinemia needed to overcome the insulin resistance, type 2 diabetes develops. 2, 3 Most people can sustain the level of compensatory hyperinsulinemia needed to maintain normal or near-normal glucose tolerance. Although the compensatory hyperinsulinemia prevents the development of frank hyper-glycemia, insulin-resistant/hyperinsulinemic individuals are at higher risk of having glucose intolerance, a high plasma triglyceride and a low concentration of high-density lipoprotein cholesterol (HDL-C), and essential hypertension. In 1988 Reaven 4 proposed that those who display a cluster of abnormalities associated with insulin resistance/compensatory hyperinsulinemia are at significantly increased risk for cardiovascular diseases. He termed this constellation of metabolic abnormalities syndrome X, which has since been known as Reaven syndrome, insulin resistance syndrome (IRS) or metabolic syndrome.
In patients at high risk for cardiovascular diseases, endothelial dysfunction is observed even before the onset of clinically manifest vascular disease. Indeed, there are several lines of evidence indicating that endothelial function is compromised in situations with reduced sensitivity to endogenous insulin. A decreased bioavailability of nitric oxide (NO) is a crucial factor for the development of endothelial dysfunction (for review see Cooke 5 ) and, furthermore, seems to play an important role in the development of insulin resistance. Endothelium-derived NO synthase (NOS) regulates blood flow to insulin-sensitive tissues (i.e. skeletal muscle, liver, adipose tissue), and its activity is impaired in insulin-resistant individuals. Inhibition of NOS impairs microvascular recruitment and blunts muscle glucose uptake in response to insulin. 6 In rats, induction of hypertension by the administration of the NOS inhibitor N G -monomethyl-L-arginine (L-NMMA) is associated with insulin resistance. 7 There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) contribute to endothelial dysfunction. [8] [9] [10] Plasma ADMA levels are elevated in patients with various cardiovascular risk factors and/or clinical disorders (for review see Cooke 11 ). Furthermore, plasma ADMA levels predict all-cause and cardiovascular mortality in patients with chronic renal insufficiency and acute coronary events. 12, 13 An intriguing relationship has been demonstrated between insulin resistance and ADMA plasma concentrations. 14 This review will briefly focus on the different concepts describing disorders of glucose/insulin homeostasis (i.e. syndrome X, metabolic syndrome, and IRS). Thereafter, we will summarize studies demonstrating the importance of NO bioavailability in the context of insulin resistance. Finally, we will address the question of whether elevated plasma concentrations of the endogenous NOS inhibitor ADMA may play a role in the development of insulin resistance.
Definition of the syndrome
Insulin-mediated glucose disposal varies six-to eightfold in apparently healthy individuals without diabetes. 1 In a patient with metabolic syndrome, not all tissues share the defect in insulin sensitivity that occurs in the muscle and adipose tissue. As a result, the compensatory hyperinsulinemia has an adverse impact on tissues that remain insulin sensitive. This concept of regional differences in insulin sensitivity is essential for the understanding of the abnormalities and clinical syndromes associated with insulin resistance.
Syndrome X
Reaven proposed in 1988 4 that individuals who displayed the cluster of abnormalities associated with insulin resistance/compensatory hyperinsulinemia were at significantly higher risk for cardiovascular diseases. This cluster of related abnormalities was subsumed under the term syndrome X. However, since the introduction of the concept of syndrome X, there has been an increasing amount of new insights that are relevant to the role of insulin resistance in human diseases. This resulted in the evolution of a conceptual framework for understanding syndrome X and its consequences. Two new terms have arisen to describe the clinical syndrome (metabolic syndrome) or the pathophysiological abnormality (IRS).
Metabolic syndrome
The report of the adult treatment panel III (ATP III) of the National Cholesterol Education Program recognized the link between a defect of insulin action and an increased risk for the development of cardiovascular diseases. 15 The five criteria for identifying individuals with the metabolic syndrome are: abdominal obesity (determined by measurement of waist circumference), fasting glucose (Ն110 Ͻ126 mg/dl), blood pressure (Ն130/80 mmHg), triglycerides (Ն150 mg/dl), and HDL-C (Ͻ40 mg/dl for men, Ͻ50 mg/dl for women). The metabolic syndrome is present when three or more of the five criteria are met. However, the primary goal of the ATP III in establishing criteria for making the diagnosis of the metabolic syndrome was to identify people at increased risk for cardiovascular diseases exclusively, and to initiate changes to decrease the risk.
Insulin resistance syndrome
The metabolic syndrome is useful in clinical practice, but is not based on an assessment of the underlying pathophysiological mechanism. Accordingly, Reaven proposed the term insulin resistance syndrome (IRS) to provide a conceptual framework based on pathophysiology. 16 In contrast to the metabolic syndrome, the IRS is a term used to describe a cluster of abnormalities and related clinical outcomes that occur more commonly in insulin-resistant/hyperinsulinemic individuals. Insulin resistance is not a disease but rather a physiologic abnormality that increases the likelihood that one or more of the abnormalities associated with insulin resistance/compensatory hyperinsulinemia will be present. Furthermore, insulin resistance is not a categorical variable, but, like hypertension, is best conceived of as a range of elevated values occurring at one end of the spectrum of insulin sensitivity throughout a population of individuals.
Several abnormalities have been demonstrated to be associated with insulin resistance. Insulin-resistant individuals may be glucose intolerant, as manifest by an elevated fasting glucose level or glucose tolerance test. Frequently, dyslipidemia is present, characterized by an increase of plasma triglycerides and low-density lipoprotein cholesterol (LDL-C) levels, a decrease in plasma HDL-C and a postprandial accumulation of triglyceride-rich lipoproteins. Furthermore, markers of inflammation (i.e. C-reactive protein, white blood cell count) are elevated, 17 as well as prothrombotic factors such as plasminogen activator inhibitor-1 and fibrinogen. 18 In addition, abnormal uric acid metabolism resulting in the accumulation of uric acid is observed in humans. It is interesting to note that endothelial dysfunction is associated with insulin resistance. There are increased plasma levels of soluble adhesion molecules, augmented adhesiveness of circulating leukocytes, and endothelium-dependent, NO-mediated vasodilation is markedly impaired. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In addition, activation of the sympathetic nervous system and increased renal sodium retention lead to hemodynamic changes in those who are insulin resistant.
Since these abnormalities occur more commonly in insulin-resistant individuals, they are at increased risk for developing associated clinical syndromes (e.g. type 2 diabetes, cardiovascular diseases, essential hypertension, polycystic ovary syndrome, nonalcoholic fatty liver disease, sleep apnea and/or certain forms of cancer). The abnormalities and clinical syndromes can occur in the absence of insulin resistance. Furthermore, insulin-resistant individuals do not necessarily develop any of the other clinical features of metabolic syndrome.
Endothelial dysfunction: cause or effect of the insulin resistance syndrome?
Endothelium-derived NO (eNOS) plays a crucial role in the regulation of vascular tone, platelet activity, leukocyte adhesion and the development of atherosclerosis (for review see Cooke 5 ). All known risk factors for atherosclerosis (i.e. hypercholesterolemia, diabetes mellitus, hypertension and chronic smoking) are associated with endothelial vasodilator dysfunction secondary to reduced vascular NO bioavailability. Flow-dependent vasodilation is mediated in part by NO. 22 NO synthesis by the vascular endothelium regulates arterial blood pressure 23, 24 and is defective in human essential hypertension. 25 Several studies have demonstrated that the impairment of endothelium-dependent vasodilation occurs in coronary and in peripheral conductance and resistance vessels, respectively. 26, 27 Impaired endothelium-dependent vasodilation of coronary 28 or peripheral vasculature 29 correlates positively with an increased risk for cardiovascular events and is an independent predictor of vascular morbidity and mortality.
In addition, the endothelium transports small molecules, macromolecules and hormones such as insulin; produces a panoply of factors that regulate vascular tone, vascular growth and blood fluidity; degrades lipoprotein particles; and mediates leukocyte trafficking. A diffuse endothelial dysfunction occurs in large arteries and plays a dynamic role in the atherothrombotic process. 30 In parallel, endothelial dysfunction in metabolically important capillary beds may participate in the development of the insulin resistance syndrome. 31 Individuals with atherosclerosis exhibit both endothelial vasodilator dysfunction and impaired insulin action. To test the hypothesis that obesity/ insulin resistance impairs both endothelium-dependent vasodilation and insulin-mediated augmentation of endothelium-dependent vasodilation, Steinberg et al 32 studied leg blood flow responses to graded intrafemoral artery infusions of metacholine chloride (endothelium-dependent) or sodium nitroprusside (endothelium-independent) during saline infusion and euglycemic hyperinsulinemia in lean insulin-sensitive controls, in obese insulin-resistant individuals, and in people with noninsulin-dependent diabetes mellitus (NIDDM). In this particular study, obesity/insulin resistance was associated with blunted endotheliumdependent but normal endothelium-independent, vasodilation and a failure of euglycemic hyperinsulinemia to augment endothelium-dependent vasodilation. Obese/insulin-resistant individuals were characterized by endothelial vasodilator dysfunction and resistance to insulin's effect to induce endothelium-dependent vasodilation.
Endothelial dysfunction occurs early in the insulinresistant state. Insulin-resistant individuals, notably those with type 2 diabetes and obesity, have impaired skeletal blood flow and reduced peripheral glucose uptake in the face of high insulin levels. 33 Insulinresistant Mexican Americans have a significant reduction in coronary vasodilation to cold pressor testing. 34 Epidemiological studies indicate that two major determinants of human morbidity and mortality, arterial hypertension and insulin resistance, are related. 35, 36 Persistence of the metabolic defects after normalization of the blood pressure by pharmacological agents 37 and their absence in secondary forms of human hypertension 38 suggest a common cause for the metabolic and hemodynamic abnormalities.
Interaction between insulin and NO in modulating insulin sensitivity
Insulin itself, in addition to its metabolic actions (i.e. the regulation of glucose, fatty acid and amino acid metabolism), directly affects the endothelium and smooth muscle cells. Insulin, at normal physiologic concentrations, increases skeletal muscle blood flow in healthy, insulin-sensitive people. The insulin effect to vasodilate skeletal muscle vasculature is directly proportional to its ability to stimulate glucose uptake. 39 In other words, insulin sensitivity and vasodilation are linked such that the most insulinsensitive individuals exhibit the greatest degree of vasodilation in response to insulin. Conversely, insulin-resistant people such as those who are obese and NIDDM patients exhibit blunted vasodilatory responses to insulin.
Insulin enhances both skeletal muscle glucose disposal and total leg blood flow in a time-and dose-dependent fashion. 40, 41 It has been proposed that increasing blood flow by this action on resistance vessels could facilitate the delivery of glucose and insulin and thereby contribute to overall glucose disposal. 40 However, observations that insulin-induced increases in total muscle blood flow temporally lag significantly behind the stimulation of muscle glucose uptake, 41 and that this flow effect requires relatively high insulin concentrations, have led to controversy regarding the physiological significance of insulin-induced flow increases. 41, 42 However, insulin-induced microvascular recruitment in skeletal muscle may be a possible explanation for this phenomenon. While insulin required 120 min to augment rat hindlimb blood flow, it increased microvascular volume in skeletal muscle within 30 min, and this effect persisted throughout the insulin infusion, 43 implying that small terminal arterioles respond more promptly to insulin than the resistance vessels. 6 Vincent et al 44 investigated whether this arises as a direct vascular response to insulin or indirectly from insulin-induced effects on muscle metabolic function. These investigators compared the temporal sequence of vascular and metabolic responses to a 30 min physiologic infusion of insulin (3 mU/min/kg, euglycemic clamp) or saline in rat skeletal muscle in vivo. Insulin rapidly recruited skeletal muscle capillaries in vivo by a NO-dependent action, and the increase in capillary recruitment may contribute to the subsequent glucose uptake.
Increases in the rates of glucose uptake and metabolism in skeletal muscle occur by at least two distinct signaling cascades: insulin-mediated and/or contractionstimulated pathways. 45, 46 Furthermore, exogenously administered NO, which is generated from the NO donor sodium nitroprusside, is able to stimulate glucose transport in isolated skeletal muscles [47] [48] [49] by increasing glucose transporter 4 (GLUT4) levels at the cell surface. 49 Therefore, some reports suggest that NO is a critical mediator of insulin-and/or contractionstimulated glucose transport. Data by Steinberg et al 50 underlined the important role of endothelium-derived NO as a potential mechanism responsible for linking insulin action and vasodilation. These investigators hypothesized that insulin caused NO-dependent vasodilation by either stimulating the synthesis/release of NO or sensitizing the vascular smooth muscle to NO. Substantial evidence accumulating over recent years has suggested that NO is involved in insulin's action to increase limb blood flow in humans. [50] [51] [52] [53] [54] It is interesting to note that, in eNOS Ϫ/Ϫ mice, insulin stimulation of muscle blood flow was impaired. 55 Moreover, insulin stimulation of muscle blood flow and stimulation of muscle glucose uptake were strongly related.
Insulin's effect on the endothelium is mediated through its own receptor and insulin signaling pathways, resulting in an increased production and/or release of NO. NO in muscle is produced by NOS, located in both vascular endothelium (eNOS) 56 and myocytes (nNOS). 57 Insulin has been shown to activate directly a signaling cascade in cultured endothelial cells via insulin receptor substrate 1, phosphatidylinositol 3-kinase and protein kinase B, which can then phosphorylate and activate eNOS. [58] [59] [60] In cultured human vascular endothelial cells, insulin increased cyclic guanosine monophosphate (cGMP) production by inducing NO synthesis. The insulinmediated glucose disposal (and the corresponding GLUT4 recruitment into the plasma membrane) was mediated by an increased NO synthesis, which stimulated cGMP production and the subsequent activation of a cGMP-dependent protein kinase. 61 NO stimulated glucose transport and the rates of lactate release and glucose oxidation in isolated incubated rat skeletal muscle preparations. 48 The effector mechanism(s) used by NO to stimulate glucose metabolism in skeletal muscle are not well characterized. It is suggested that NO interacts with the heme group bound to soluble guanylate cyclase, leading to activation and elevation of cGMP levels. 62 Indeed, the NO donor sodium nitroprusside stimulates the generation of cGMP in isolated rat skeletal muscle, as well as the rate of glucose utilization.
Recently it has been shown that AMP-activated protein kinase (AMPK) is activated by exercise in skeletal muscle. 63 Once activated, AMPK responds by switching off ATP utilizing processes, such as fatty acid synthesis and cholesterol synthesis, 64 and by switching on ATP-generating pathways, such as fatty acid oxidation. 65 A number of recent studies have suggested that AMPK may play an important role in regulating energy metabolism in skeletal muscle. It has been postulated, therefore, that AMPK may be the link between exercise and glucose transport. AMPK co-immunoprecipitates with eNOS in rat cardiac muscle, and is able to phosporylate and activate eNOS in vitro. 66 Studies by Fryer et al 67 showed that NOS activity in H-2Kb cells was activated after pharmacological stimulation of AMPK. Treatment of these cells or rat muscle with NOS inhibitors completely blocked the increase in glucose transport after activation of AMPK. In addition, an inhibitor of guanylate cyclase also blocked transport of glucose, indicating that activation of AMPK in muscle cells stimulates glucose transport by activation of NOS coupled to downstream NO signaling components, including cGMP. Recently, Higaki et al 68 demonstrated that NO-stimulated glucose uptake is associated with an activation of the ␣1 catalytic subunit of AMPK.
A decreased NO bioavailability is linked to insulin resistance
Inhibition of NO production by L-NMMA, a competitive inhibitor of all NOS isoforms, can fully abolish the effects of insulin to increase limb total blood flow in humans. 50, 51, 54, 69 In one particular study, L-NMMA partially blocked insulin-mediated glucose uptake. 51 Furthermore, intravenous administration of L-NMMA in rats acutely induced hypertension and insulin resistance. 7 Importantly, L-NMMA causes constriction of small-resistance arterioles, which control microcirculatory flow and capillary recruitment. 70, 71 Chen and Messina 52 demonstrated that insulin-induced vasodilation of first-order arterioles in rat cremaster and administration of the NOS inhibitor N G -nitro-L-arginine (L-NNA) or removal of the endothelium prevented this dilation. In addition, studies by Vincent et al 6 demonstrated that inhibition of NOS with N G -nitro-L-arginine-methyl ester (L-NAME) blocked the microvascular recruitment and blunted muscle glucose uptake in response to insulin. Similar to the effect of NOS inhibition in the periphery, acute pharmacologic blockade of NOS activity in the central nervous system by intracerebroventricular administration of L-NMMA resulted in peripheral insulin resistance and insulin secretory defects in unrestrained conscious rats. 72 The relationship between NOS and insulin resistance has been investigated using different knockout models. It is intriguing that mice lacking eNOS or nNOS are more likely to develop insulin resistance. Shankar et al 73 performed hyperinsulinemic-euglycemic clamp studies after a 24-hour fast, during an insulin infusion. The glucose infusion rate was significantly reduced in the eNOS knockout mice compared with the wild-type counterparts, with values for the nNOS knockout mice being intermediate. The endogenous glucose output was completely suppressed in the nNOS knockout and wild-type mice during insulin infusion, but not in the eNOS knockout mice. In addition, the eNOS knockout mice displayed significantly reduced whole-body glucose disposal rates compared with wild-type mice. These data indicate that different NOS isoforms are modulating insulin sensitivity with different tissue preferences. Duplain et al 55 tested the hypothesis that a defect of eNOS may not only result in arterial hypertension but also cause insulin resistance, by performing euglycemic hyperinsulinemic clamp studies in conscious wild-type (eNOS ϩ/ϩ ) and homozygote eNOS-deficient (eNOS Ϫ/Ϫ ) mice. They measured hindlimb muscle blood flow during clamp studies in vivo and assessed basal and insulin-stimulated glucose uptake in isolated skeletal muscle preparations in vitro. In this particular study, the eNOS Ϫ/Ϫ mice were hypertensive and had fasting hyperinsulinemia, hyperlipidemia and a 40% lower insulin-stimulated glucose uptake than control mice. The development of insulin resistance in the eNOS Ϫ/Ϫ mice was related specifically to impaired NO synthesis, since in equally hypertensive 1-kidney/1-clip mice (a model of renovascular hypertension) insulin-stimulated glucose uptake was normal.
Taken together, NOS and/or NO bioavailability seem to play a major role in the regulation of insulin sensitivity. Therefore, maintaining and/or restoring NO bioavailability seem to be important factors in modulating insulin sensitivity and in preventing the development of insulin resistance.
ADMA an endogenous NOS inhibitor
ADMA is an endogenous NOS inhibitor. Vallance et al demonstrated in 1992 that ADMA plasma concentrations are elevated in patients with renal insufficiency. 8 Raised ADMA plasma concentrations may contribute to the vascular pathophysiology observed in atherosclerosis and in the IRS, and are associated with abnormalities closely related to this syndrome. These conditions include hypertriglyceridemia, 74 hyperglycemia, 75, 76 and hypertension. 77, 78 Furthermore, ADMA levels are elevated in a variety of clinical disorders (for review see Cooke 11 ). Moreover, ADMA appears to be an independent predictor of acute coronary events, and of cardiovascular and overall mortality. 12, 13 ADMA and endothelial dysfunction Since the acute vasodilating effect of insulin is primarily NO-mediated, an attenuated response to insulin under insulin-resistant conditions could be due to ADMA-mediated endothelial dysfunction. Vallance et al 8 provided in vitro and in vivo evidence that NO synthesis can be inhibited by ADMA. ADMA caused endothelium-dependent contraction of isolated vessels (due to inhibition of eNOS), attenuated endotheliumdependent relaxation, elevated blood pressure when infused into guinea-pigs, and caused vasoconstriction in the human forearm (8.3% fall in forearm blood flow after 8 mol/min ADMA infusion). More recently, Achan et al 9 investigated the cardiovascular effects of ADMA in healthy volunteers in vivo in a randomized, double-blind, placebo-controlled study. An intravenous injection of ADMA (3 mg/kg up to a maximum of 250 mg) significantly reduced heart rate and cardiac output (by 9.2% and 14.8%, respectively). Volunteers receiving ADMA also showed an impaired cardiac output response to upper limb exercise, and an increase in blood pressure and systemic vascular resistance. Furthermore, in patients with cardiovascular diseases and elevated ADMA levels, cardiac output was significantly lower, and systemic vascular resistance was increased. 10 Infusion of ADMA (0.25 mg/kg/min) or L-NAME resulted in a comparable decrease in effective renal plasma flow and an increase in renovascular resistance.
ADMA, hyperglycemia and insulin resistance
Lin et al 75 demonstrated that vascular smooth muscle cells and human endothelial cells exposed to high glucose concentrations (25.5 mmol/l) for 48 hours had significantly elevated ADMA concentrations in the cell supernatant, accompanied by a reduced activity of the enzyme responsible for ADMA degradation, dimethylarginine dimethylaminohydrolase (DDAH), and reduced cGMP formation. In human endothelial cells, co-incubation with the antioxidant polyethylene glycol-conjugated superoxide dismutase reversed the effects of a high glucose concentration on DDAH activity, ADMA accumulation, and cGMP synthesis, suggesting increased oxidative stress causing hyperglycemia-induced elevation of ADMA. In addition, Abbasi et al 76 demonstrated that ADMA plasma concentrations were elevated in patients with type 2 diabetes.
An intriguing relationship has been demonstrated between elevated ADMA levels and insulin resistance. 14 ADMA was positively correlated with the impairment of insulin-mediated glucose disposal in nondiabetic, normotensive individuals. Consistent with the insulin resistance syndrome, ADMA concentrations were increased in insulin-resistant individuals independent of hypertension and correlated with fasting triglycerides, but not with LDL-C levels. In insulinresistant individuals with hypertension, treatment with rosiglitazone improved insulin sensitivity and, interestingly, reduced plasma ADMA concentrations.
Similarly, metformin has been shown to decrease circulating ADMA, both as monotherapy and as addon therapy to sulphonylurea in poorly controlled type 2 diabetic patients. 79 Several studies have shown that treatment with rosiglitazone 80, 81 or metformin 82, 83 was able to improve endothelial function in humans and rodents. Treatment with both rosiglitazone and metformin resulted in favorable changes in metabolic risk factors in addition to improving insulin resistance. The observed reduction in ADMA levels could be due to the insulin sensitivity and reduced oxidative stress. However, could it be that ADMA also contributes to insulin resistance?
ADMA is derived from proteins that have been post-translationally methylated and subsequently hydrolyzed to release free ADMA. ADMA is secreted into body fluids and excreted in the urine. However, the major pathway for elimination of ADMA is its metabolism by the DDAH enzyme. Recently, DDAH-1 transgenic mice have been generated in our laboratory. 84 Genetic manipulation by overexpressing the DDAH enzyme reduces ADMA plasma concentrations. DDAH transgenic mice show increased DDAH activity, decreased ADMA plasma concentrations, and increased systemic NO production. In conscious DDAH animals, the systolic blood pressure was significantly lower than that of age-and weight-matched wild-type littermates. In anesthetized animals, there was an even larger difference in systolic blood pressure, measured by cannulation of the carotid artery. This was associated with a 10% increase in heart rate. The cardiac output in the DDAH animals was similar to that of the control animals, whereas the calculated stroke volume was reduced by 10%. Furthermore, the calculated systemic vascular resistance tended to be lower in the DDAH animals. Preliminary studies indicate that these animals are in fact insulin sensitive.
Therefore, based on the relationship between reduced NO bioavailability, endothelial dysfunction and insulin resistance described above, this transgenic animal model seems to be an excellent tool to investigate the role of ADMA in modulating insulin sensitivity.
How may impaired NO bioavailability lead to insulin resistance?
Pinkney et al 31 hypothesized that endothelial dysfunction precedes the development of both the IRS and atherosclerosis. The IRS is a marker for peripheral endothelial dysfunction. In large and medium-sized arteries endothelial dysfunction plays a major role in atherogenesis but has little direct metabolic impact. By contrast, the endothelial dysfunction in the microvasculature contributes to the IRS. The coexistence of central and peripheral endothelial dysfunction may explain the observed association between atherosclerotic vascular disease and IRS.
Insulin resistance under conditions of an impaired NO bioavailability could be related to a vascular and/or cellular defect. The endothelium has important roles both in the delivery of insulin to the tissues and as a target for insulin action. Insulin acts as a vasodilator and, in insulin-resistant states, including obesity, hypertension and NIDDM, an impaired insulinmediated increase in skeletal muscle blood flow has been described. 40 Insulin-resistant individuals have reduced skeletal muscle capillarization. 85, 86 Thus, both reduced capillary surface area and impaired capillary endothelial function, along with a failure of endothelial vasodilator response to insulin in arterioles, could contribute to insulin resistance through delayed insulin delivery to the interstitial fluid.
In addition, other studies have highlighted the importance of the capillary endothelium in the transport of insulin from the vascular to the interstitial compartment. Jansson et al 87 demonstrated that the endothelium is a barrier to insulin and that changes in plasma insulin concentrations are followed by slower changes in interstitial insulin. Insulin-resistant individuals also show a delay in transendothelial delivery of insulin to the interstitial space. 88 Resistance at the tissue level contributes to insulin resistance, as in steady-state studies the interstitial insulin concentration is not the main determinant of insulin action. In the dynamic state, as insulin levels change, active or passive transendothelial insulin transport assumes greater importance, with a rate-limiting step before insulin binding to its receptor. 89 Alternatively, NO may have effects on glucose uptake that are independent of its vascular action. NOS is expressed in skeletal muscle tissue, 90 where NO regulates metabolic and contractile processes. 91 In rat skeletal muscle preparations, pharmacological NOS inhibition decreased basal glucose transport in some 91 but not all studies. 90, 92 Again, in eNOS Ϫ/Ϫ mice, basal and insulin-stimulated glucose transport were lower in isolated skeletal muscle preparations compared with wild-type mice.
Taken together, these findings suggest that defects in insulin stimulation of muscle perfusion and insulin signaling in the skeletal muscle cell contribute to metabolic insulin resistance under conditions of a decreased NO bioavailability.
Conclusions
The present review summarizes a possible interaction between a decreased NO bioavailability, endothelial dysfunction and the development of insulin resistance. In this context, increased plasma concentrations of the endogenous NOS inhibitor ADMA may play an important role in modulating insulin sensitivity. Further studies have to be performed to investigate whether endothelial dysfunction is not simply a consequence but is the driving cause of most abnormalities of the IRS. To elucidate further the importance of elevated ADMA plasma concentrations in the context of insulin resistance, the use of transgenic and/or knockout proteinarginine N-methyltransferase (PRMT) and/or DDAH mice seems to be a promising approach. Several therapeutic agents improve endothelial vasodilator function and insulin resistance: rosiglitazone, metformin, ace inhibitors and angiotensin II receptor, AT 1 -subtype blockers (AT 1 -receptor blockers). It is intriguing that these agents also lower ADMA plasma levels. Their early use may be a useful approach to prevent the development of insulin resistance and/or clinical syndromes associated with the IRS due to ADMA-mediated decreased NO bioavailability.
